Published in Malar J on May 29, 2008
Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med (2009) 33.25
Artemisinin resistance: current status and scenarios for containment. Nat Rev Microbiol (2010) 6.28
The last man standing is the most resistant: eliminating artemisinin-resistant malaria in Cambodia. Malar J (2009) 4.25
Deployment of ACT antimalarials for treatment of malaria: challenges and opportunities. Malar J (2008) 2.78
Spatial and temporal epidemiology of clinical malaria in Cambodia 2004-2013. Malar J (2014) 2.12
Barriers to prompt and effective malaria treatment among the poorest population in Kenya. Malar J (2010) 2.04
Socially-marketed rapid diagnostic tests and ACT in the private sector: ten years of experience in Cambodia. Malar J (2011) 1.93
No evidence of delayed parasite clearance after oral artesunate treatment of uncomplicated falciparum malaria in Mali. Am J Trop Med Hyg (2012) 1.87
Assessing the quality of service of village malaria workers to strengthen community-based malaria control in Cambodia. Malar J (2010) 1.79
Poor quality vital anti-malarials in Africa - an urgent neglected public health priority. Malar J (2011) 1.76
Focused Screening and Treatment (FSAT): a PCR-based strategy to detect malaria parasite carriers and contain drug resistant P. falciparum, Pailin, Cambodia. PLoS One (2012) 1.66
Focusing on quality patient care in the new global subsidy for malaria medicines. PLoS Med (2009) 1.63
Use and limitations of malaria rapid diagnostic testing by community health workers in war-torn Democratic Republic of Congo. Malar J (2009) 1.62
Introducing malaria rapid diagnostic tests at registered drug shops in Uganda: limitations of diagnostic testing in the reality of diagnosis. Soc Sci Med (2011) 1.60
Case management of malaria fever in Cambodia: results from national anti-malarial outlet and household surveys. Malar J (2011) 1.60
Treatment guided by rapid diagnostic tests for malaria in Tanzanian children: safety and alternative bacterial diagnoses. Malar J (2011) 1.60
Cost of increasing access to artemisinin combination therapy: the Cambodian experience. Malar J (2008) 1.55
Access to malaria treatment in young children of rural Burkina Faso. Malar J (2009) 1.41
Discovery, mechanisms of action and combination therapy of artemisinin. Expert Rev Anti Infect Ther (2009) 1.41
Scaling-up malaria treatment: a review of the performance of different providers. Malar J (2012) 1.40
An optimised age-based dosing regimen for single low-dose primaquine for blocking malaria transmission in Cambodia. BMC Med (2016) 1.39
A stratified random survey of the proportion of poor quality oral artesunate sold at medicine outlets in the Lao PDR - implications for therapeutic failure and drug resistance. Malar J (2009) 1.35
Adherence to artemisinin-based combination therapy for the treatment of malaria: a systematic review of the evidence. Malar J (2014) 1.26
Artemisinin Antimalarials: Preserving the "Magic Bullet" Drug Dev Res (2010) 1.25
The quest for universal access to effective malaria treatment: how can the AMFm contribute? Malar J (2010) 1.17
Factors associated with non-adherence to Artemisinin-based combination therapy (ACT) to malaria in a rural population from holoendemic region of western Kenya. BMC Infect Dis (2012) 1.17
Effects of malaria volunteer training on coverage and timeliness of diagnosis: a cluster randomized controlled trial in Myanmar. Malar J (2012) 1.15
History of malaria research and its contribution to the malaria control success in Suriname: a review. Malar J (2012) 1.13
Methods for evaluating delivery systems for scaling-up malaria control intervention. BMC Health Serv Res (2010) 1.13
Improving malaria knowledge and practices in rural Myanmar through a village health worker intervention: a cross-sectional study. Malar J (2014) 1.10
Quality of antimalarials at the epicenter of antimalarial drug resistance: results from an overt and mystery client survey in Cambodia. Am J Trop Med Hyg (2015) 1.07
Injections, cocktails and diviners: therapeutic flexibility in the context of malaria elimination and drug resistance in Northeast Cambodia. PLoS One (2013) 1.06
Novel approaches to risk stratification to support malaria elimination: an example from Cambodia. Malar J (2014) 1.05
Malaria and the mobile and migrant population in Cambodia: a population movement framework to inform strategies for malaria control and elimination. Malar J (2015) 1.02
Modeling within-host effects of drugs on Plasmodium falciparum transmission and prospects for malaria elimination. PLoS Comput Biol (2014) 1.01
Monitoring, characterization and control of chronic, symptomatic malaria infections in rural Zambia through monthly household visits by paid community health workers. Malar J (2014) 1.01
Effects of selected socio-demographic characteristics of community health workers on performance of home visits during pregnancy: a cross-sectional study in Busia District, Kenya. Glob J Health Sci (2012) 1.00
The clinical impact of artemisinin resistance in Southeast Asia and the potential for future spread. FEMS Microbiol Rev (2016) 0.99
Evidence of successful malaria case management policy implementation in Cambodia: results from national ACTwatch outlet surveys. Malar J (2016) 0.96
Village malaria worker performance key to the elimination of artemisinin-resistant malaria: a Western Cambodia health system assessment. Malar J (2016) 0.94
"Souls of the ancestor that knock us out" and other tales. A qualitative study to identify demand-side factors influencing malaria case management in Cambodia. Malar J (2012) 0.91
Extensive drug resistance in malaria and tuberculosis. Emerg Infect Dis (2010) 0.86
Malaria community health workers in Myanmar: a cost analysis. Malar J (2016) 0.84
Evaluation of intensified behaviour change communication strategies in an artemisinin resistance setting. Malar J (2016) 0.84
Assuring access to topical mosquito repellents within an intensive distribution scheme: a case study in a remote province of Cambodia. Malar J (2015) 0.83
Phenotypic effects of concomitant insensitive acetylcholinesterase (ace-1(R)) and knockdown resistance (kdr(R)) in Anopheles gambiae: a hindrance for insecticide resistance management for malaria vector control. Parasit Vectors (2014) 0.83
Synthesis and antimalarial activity of metal complexes of cross-bridged tetraazamacrocyclic ligands. Bioorg Med Chem (2014) 0.82
Examining equity in access to long-lasting insecticide nets and artemisinin-based combination therapy in Anambra State, Nigeria. BMC Public Health (2012) 0.81
Evaluation of community-based systems for the surveillance of day three-positive Plasmodium falciparum cases in Western Cambodia. Malar J (2014) 0.81
Are Tanzanian patients attending public facilities or private retailers more likely to adhere to artemisinin-based combination therapy? Malar J (2015) 0.80
High mobility, low access thwarts interventions among seasonal workers in the Greater Mekong Sub-region: lessons from the malaria containment project. Malar J (2016) 0.78
Plasmodium vivax Malaria in Cambodia. Am J Trop Med Hyg (2016) 0.77
Response of patent medicine vendors in rural areas of Lagos state Nigeria to antimalarial policy change. Afr Health Sci (2015) 0.76
Resistance-mediating polymorphisms of Plasmodium falciparum among isolates from children with severe malaria in kumasi, ghana. Ghana Med J (2010) 0.76
Local constraints to access appropriate malaria treatment in the context of parasite resistance in Cambodia: a qualitative study. Malar J (2017) 0.75
Treatment-seeking behaviour and associated costs for malaria in Papua, Indonesia. Malar J (2016) 0.75
Evaluation of Effectiveness of Ethanolic Extract of Artemisia aucheri, Individually and in Combination with Chloroquine, on Chloroquine - Sensitive Strain of Plasmodium berghei in Sourian Mice. Iran J Public Health (2013) 0.75
Estimating wealth effects without expenditure data--or tears: an application to educational enrollments in states of India. Demography (2001) 41.83
Changing home treatment of childhood fevers by training shop keepers in rural Kenya. Trop Med Int Health (1999) 4.43
Fake antimalarials in Southeast Asia are a major impediment to malaria control: multinational cross-sectional survey on the prevalence of fake antimalarials. Trop Med Int Health (2004) 4.35
A critical review of behavioral issues related to malaria control in sub-Saharan Africa: what contributions have social scientists made? Soc Sci Med (2004) 4.22
Improving malaria home treatment by training drug retailers in rural Kenya. Trop Med Int Health (2004) 3.65
Self-treatment for malaria: the evidence and methodological issues. Health Policy Plan (2002) 3.60
Persistence of Plasmodium falciparum HRP-2 in successfully treated acute falciparum malaria. Trans R Soc Trop Med Hyg (2001) 3.32
Self-treatment of malaria in a rural area of western Kenya. Bull World Health Organ (1995) 3.03
Large-scale malaria survey in Cambodia: novel insights on species distribution and risk factors. Malar J (2007) 2.75
Counterfeit artesunate antimalarials in southeast Asia. Lancet (2003) 2.59
Fever and its treatment among the more and less poor in sub-Saharan Africa. Health Policy Plan (2005) 2.33
Fake antimalaria drugs in Cambodia. Lancet (2001) 2.20
Multiple dose pharmacokinetics of oral artemisinin and comparison of its efficacy with that of oral artesunate in falciparum malaria patients. Trans R Soc Trop Med Hyg (1996) 1.90
In vitro monitoring of Plasmodium falciparum susceptibility to artesunate, mefloquine, quinine and chloroquine in Cambodia: 2001-2002. Acta Trop (2005) 1.68
Countrywide survey shows very high prevalence of Plasmodium falciparum multilocus resistance genotypes in Cambodia. Antimicrob Agents Chemother (2005) 1.63
Insecticide-treated bednets for the prevention of Plasmodium falciparum malaria in Cambodia: a cluster-randomized trial. Trop Med Int Health (2006) 1.58
Cost of increasing access to artemisinin combination therapy: the Cambodian experience. Malar J (2008) 1.55
Resistance to artemisinin derivatives along the Thai-Cambodian border. Wkly Epidemiol Rec (2007) 1.48
Double blind randomised clinical trial of two different regimens of oral artesunate in falciparum malaria. Southeast Asian J Trop Med Public Health (1991) 1.37
Treatment of malaria fever episodes among children in Malawi: results of a KAP survey. Trop Med Parasitol (1994) 1.28
WHO calls for an immediate halt to provision of single-drug artemisinin malaria pills. New malaria treatment guidelines issued by WHO. Saudi Med J (2006) 1.25
Double blind randomised clinical trial of oral artesunate at once or twice daily dose in falciparum malaria. Southeast Asian J Trop Med Public Health (1991) 1.21
Improving private practitioner sick-child case management in two urban communities in Pakistan. Trop Med Int Health (2002) 1.08
Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med (2009) 33.25
Overcoming health-systems constraints to achieve the Millennium Development Goals. Lancet (2004) 15.43
Typhoid fever. N Engl J Med (2002) 12.96
Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med (2014) 11.87
Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet (2012) 11.82
Vivax malaria: neglected and not benign. Am J Trop Med Hyg (2007) 10.16
Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med (2004) 10.14
Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet (2010) 8.52
Effect of artemether-lumefantrine policy and improved vector control on malaria burden in KwaZulu-Natal, South Africa. PLoS Med (2005) 8.36
Conquering the intolerable burden of malaria: what's new, what's needed: a summary. Am J Trop Med Hyg (2004) 8.13
Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study. Lancet Infect Dis (2012) 6.94
Scaling up access to antiretroviral treatment in southern Africa: who will do the job? Lancet (2004) 6.84
Rapid expansion of the health workforce in response to the HIV epidemic. N Engl J Med (2007) 6.34
Melioidosis: insights into the pathogenicity of Burkholderia pseudomallei. Nat Rev Microbiol (2006) 6.34
A major genome region underlying artemisinin resistance in malaria. Science (2012) 6.25
Mixed-species malaria infections in humans. Trends Parasitol (2004) 6.01
Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deployment. PLoS One (2009) 5.81
Standardizing the measurement of parasite clearance in falciparum malaria: the parasite clearance estimator. Malar J (2011) 5.65
Multiple populations of artemisinin-resistant Plasmodium falciparum in Cambodia. Nat Genet (2013) 5.22
Prevention of mother-to-child transmission of HIV and the health-related Millennium Development Goals: time for a public health approach. Lancet (2011) 5.00
Maternal health in poor countries: the broader context and a call for action. Lancet (2006) 4.72
Estimation of the total parasite biomass in acute falciparum malaria from plasma PfHRP2. PLoS Med (2005) 4.65
Artemisinin-based combination treatment of falciparum malaria. Am J Trop Med Hyg (2007) 4.58
Medicine sellers and malaria treatment in sub-Saharan Africa: what do they do and how can their practice be improved? Am J Trop Med Hyg (2007) 4.51
Intrahost modeling of artemisinin resistance in Plasmodium falciparum. Proc Natl Acad Sci U S A (2010) 4.50
Comparison of three fluid solutions for resuscitation in dengue shock syndrome. N Engl J Med (2005) 4.47
Manslaughter by fake artesunate in Asia--will Africa be next? PLoS Med (2006) 4.46
Analysis of Plasmodium falciparum diversity in natural infections by deep sequencing. Nature (2012) 4.37
Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites. J Infect Dis (2007) 4.35
Health financing to promote access in low income settings-how much do we know? Lancet (2004) 4.31
In vivo parasitological measures of artemisinin susceptibility. J Infect Dis (2010) 4.25
The last man standing is the most resistant: eliminating artemisinin-resistant malaria in Cambodia. Malar J (2009) 4.25
The Millennium Development Goals: a cross-sectoral analysis and principles for goal setting after 2015 Lancet and London International Development Centre Commission. Lancet (2010) 4.24
Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria. Clin Infect Dis (2006) 4.14
Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet (2004) 4.14
Genetic loci associated with delayed clearance of Plasmodium falciparum following artemisinin treatment in Southeast Asia. Proc Natl Acad Sci U S A (2012) 4.10
Early origin and recent expansion of Plasmodium falciparum. Science (2003) 4.07
Good Health at Low Cost 25 years on: lessons for the future of health systems strengthening. Lancet (2013) 4.03
The impact of response to the results of diagnostic tests for malaria: cost-benefit analysis. BMJ (2008) 4.02
Task shifting: the answer to the human resources crisis in Africa? Hum Resour Health (2009) 4.00
Counterfeit anti-infective drugs. Lancet Infect Dis (2006) 3.91
Efficacy and effectiveness of dihydroartemisinin-piperaquine versus artesunate-mefloquine in falciparum malaria: an open-label randomised comparison. Lancet (2006) 3.90
Rickettsial infections and fever, Vientiane, Laos. Emerg Infect Dis (2006) 3.87
High heritability of malaria parasite clearance rate indicates a genetic basis for artemisinin resistance in western Cambodia. J Infect Dis (2010) 3.81
When staff is underpaid: dealing with the individual coping strategies of health personnel. Bull World Health Organ (2002) 3.77
Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial. Lancet (2004) 3.72
Improving the health of the global poor. Science (2002) 3.69
A selective sweep driven by pyrimethamine treatment in southeast asian malaria parasites. Mol Biol Evol (2003) 3.67
Mobilising financial resources for maternal health. Lancet (2006) 3.53
Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria. Br J Clin Pharmacol (2004) 3.48
Malaria: current status of control, diagnosis, treatment, and a proposed agenda for research and development. Lancet Infect Dis (2002) 3.46
The cost-effectiveness of parasitologic diagnosis for malaria-suspected patients in an era of combination therapy. Am J Trop Med Hyg (2007) 3.44
Efficacy and safety of dihydroartemisinin-piperaquine (Artekin) in Cambodian children and adults with uncomplicated falciparum malaria. Clin Infect Dis (2002) 3.40
Community health workers for ART in sub-Saharan Africa: learning from experience--capitalizing on new opportunities. Hum Resour Health (2009) 3.34
Assessing capacity for health policy and systems research in low and middle income countries* Health Res Policy Syst (2003) 3.29
Poverty and user fees for public health care in low-income countries: lessons from Uganda and Cambodia. Lancet (2006) 3.24
Retail supply of malaria-related drugs in rural Tanzania: risks and opportunities. Trop Med Int Health (2004) 3.22
Two nonrecombining sympatric forms of the human malaria parasite Plasmodium ovale occur globally. J Infect Dis (2010) 3.21
The 'diagonal' approach to Global Fund financing: a cure for the broader malaise of health systems? Global Health (2008) 3.18
The global threat of counterfeit drugs: why industry and governments must communicate the dangers. PLoS Med (2005) 3.15
A randomized, controlled study of a simple, once-daily regimen of dihydroartemisinin-piperaquine for the treatment of uncomplicated, multidrug-resistant falciparum malaria. Clin Infect Dis (2005) 3.15
Health-financing reforms in southeast Asia: challenges in achieving universal coverage. Lancet (2011) 3.14
In vivo susceptibility of Plasmodium falciparum to artesunate in Binh Phuoc Province, Vietnam. Malar J (2012) 3.13
How much fat is necessary to optimize lumefantrine oral bioavailability? Trop Med Int Health (2007) 3.13
Financing of health systems to achieve the health Millennium Development Goals in low-income countries. Lancet (2010) 3.10
Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial. Lancet Infect Dis (2010) 3.08
The relationship between age and the manifestations of and mortality associated with severe malaria. Clin Infect Dis (2008) 3.05
Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients. Clin Infect Dis (2009) 3.05
The real challenges for scaling up ART in sub-Saharan Africa. AIDS (2006) 3.02
How do patients use antimalarial drugs? A review of the evidence. Trop Med Int Health (2005) 2.95
An iatrogenic pandemic of panic. BMJ (2006) 2.89
Addressing access barriers to health services: an analytical framework for selecting appropriate interventions in low-income Asian countries. Health Policy Plan (2011) 2.88
Spurious amplification of a Plasmodium vivax small-subunit RNA gene by use of primers currently used to detect P. knowlesi. J Clin Microbiol (2009) 2.85
Countdown to 2015: assessment of donor assistance to maternal, newborn, and child health between 2003 and 2006. Lancet (2008) 2.83
Randomized, controlled dose-optimization studies of dihydroartemisinin-piperaquine for the treatment of uncomplicated multidrug-resistant falciparum malaria in Thailand. J Infect Dis (2004) 2.82
Is private health care the answer to the health problems of the world's poor? PLoS Med (2008) 2.82
Central role of the spleen in malaria parasite clearance. J Infect Dis (2002) 2.80
In vivo assessment of drug efficacy against Plasmodium falciparum malaria: duration of follow-up. Antimicrob Agents Chemother (2004) 2.77
Antimalarial drug toxicity: a review. Drug Saf (2004) 2.76
Towards high-throughput molecular detection of Plasmodium: new approaches and molecular markers. Malar J (2009) 2.76
Exploring the contribution of candidate genes to artemisinin resistance in Plasmodium falciparum. Antimicrob Agents Chemother (2010) 2.68
Clinical research in resource-limited settings: enhancing research capacity and working together to make trials less complicated. PLoS Negl Trop Dis (2010) 2.68
A dominant clone of Leptospira interrogans associated with an outbreak of human leptospirosis in Thailand. PLoS Negl Trop Dis (2007) 2.65
Counterfeit artesunate antimalarials in southeast Asia. Lancet (2003) 2.59
Editorial: clinical trials in tropical diseases: a politically incorrect view. Trop Med Int Health (2006) 2.59
Reduced microcirculatory flow in severe falciparum malaria: pathophysiology and electron-microscopic pathology. Acta Trop (2004) 2.58
Community-acquired bacterial bloodstream infections in developing countries in south and southeast Asia: a systematic review. Lancet Infect Dis (2012) 2.58
Short communication: An assessment of the use of malaria rapid tests by village health volunteers in rural Laos. Trop Med Int Health (2004) 2.56
Murder by fake drugs. BMJ (2002) 2.54
Artemisinin resistance in Plasmodium falciparum is associated with an altered temporal pattern of transcription. BMC Genomics (2011) 2.53
Rapid scale-up of antiretroviral treatment in Ethiopia: successes and system-wide effects. PLoS Med (2009) 2.52
Artemisinin-based combinations. Curr Opin Infect Dis (2005) 2.51
Plasmodium falciparum genome-wide scans for positive selection, recombination hot spots and resistance to antimalarial drugs. Nat Genet (2010) 2.48
An ultrastructural study of the brain in fatal Plasmodium falciparum malaria. Am J Trop Med Hyg (2003) 2.47
The economic impact of malaria in Africa: a critical review of the evidence. Health Policy (2003) 2.42
Contrasting genetic structure in Plasmodium vivax populations from Asia and South America. Int J Parasitol (2007) 2.41
Antimalarial dosing regimens and drug resistance. Trends Parasitol (2008) 2.40
Access to medicines from a health system perspective. Health Policy Plan (2012) 2.39
Stage-dependent production and release of histidine-rich protein 2 by Plasmodium falciparum. Trans R Soc Trop Med Hyg (2005) 2.38
The influence of HIV infection on clinical presentation, response to treatment, and outcome in adults with Tuberculous meningitis. J Infect Dis (2005) 2.38